TSXV: VIMYInvestor Centre
Vimy Pharma
Contact us

About Vimy Pharma

Canadian roots. Global impact.

A national pharmaceutical company built to produce an abundant, reliable supply of high-quality, affordable essential medicines.

Founded
July 2024
Listed
TSXV: VIMY
Headquarters
Toronto, Ontario
Manufacturing
Canada

Our purpose

Vimy Pharma exists to give Canadians a reliable, affordable, Canadian-manufactured supply of essential medicines, starting with generic semaglutide.

We are a national company. Headquartered in Toronto, we developed our first batches in the GTA and will now manufacture at multiple Canadian sites.

Our team brings decades of experience taking medicines through Health Canada, including the original Canadian approval of Ozempic®. Today we have two generic submissions under way, referencing Ozempic® and Wegovy®.

Dave Suchon and Farris Smith in Ottawa.
Farris Smith and Dave Suchon with members of the Dalton research team.

Pharmaceutical sovereignty

Making essential medicines at home builds resilience into Canada’s healthcare system: reliable supply, skilled Canadian jobs, and value that stays in the country.

Manufactured in Canada

More Canadians are seeking treatment

5 million

Canadians living with type 2 diabetes1

10 million

Canadians living with obesity2

1 million+

Canadians currently treated with injectable semaglutide3

More than 2 million Canadian adults are interested in a GLP-1 medication but are not taking one, many because of cost.4

  1. Diabetes Canada, Diabetes in Canada: Backgrounder, October 2024.
  2. Obesity Canada prevalence (26.4%) applied to Statistics Canada’s population estimate, July 1, 2026; about 11.0 million, rounded down.
  3. IQVIA Canada, semaglutide unit sales, MAT; equivalent to more than 1 million patients treated for a full year.
  4. Leger Healthcare survey, February 2026, reported in N. Ireland, “3 million Canadians use GLP-1 drugs,” CBC News / The Canadian Press, March 4, 2026.

Manufactured in Canada

Vimy-semaglutide and Vimy-semaglutide (WT) will be made at multiple sites across Canada, including on a Steriline vial production line at Canada’s Critical Medicines Production Centre in Edmonton, Alberta.

Manufacturing here, to Health Canada’s rigorous standards, gives Canadians a domestic source of a W.H.O. essential medicine, with an initial capacity of 10 million units a year and plans to quadruple it over the coming years.1

Steriline vial production line for Vimy-semaglutide and Vimy-semaglutide (WT) at Canada’s Critical Medicines Production Centre.

A widening gap

Canada’s pharmaceutical trade deficit has nearly tripled in under a decade. Over time, we believe increased domestic production can substantially narrow it, and keep more intellectual property and economic value in Canada.

Canada’s pharmaceutical trade deficit, C$ billions

Source: Statistics Canada Trade Data Online; ISED Canadian Industry Statistics (NAICS 32541), 2016–2025.

Value that stays in Canada

Taxes in Canada

Vimy Pharma’s full profit margin will be taxed by the CRA.

Skilled jobs

High-value life sciences employment in Ontario, Alberta and beyond.

Manufacturing capacity

Contributing to Canada’s advanced manufacturing base for essential medicines.

Priority for domestic supply

Health Canada has proposed a pilot to prioritize generic submissions involving domestic manufacturing.2

  1. Company estimate. Capacity and expansion plans are forward-looking and subject to regulatory approval, financing and operational factors.
  2. Health Canada, “Notice: Health Canada seeks feedback on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue,” July 15, 2026.

Management

DS

Dave Suchon

CEO, Co-Founder & Director
  • 20+ years in Canadian pharma
  • 12 years in executive leadership at Novo Nordisk
  • Led the Health Canada approval of Ozempic®
  • Biochemistry study and research in protein chemistry
  • Pharma regulatory lawyer and patent litigator
FS

Farris Smith

President, Co-Founder & Director
  • 25+ years in global pharma, 20 at Novo Nordisk
  • Novo Nordisk regional CFO and management roles across Europe, LATAM, Middle East & Africa, and Canada
  • North American CFO, LEO Pharma
  • Strategic Advisor, Arch Biopartners (TSXV: ARCH)
CB

Chris Burkett

COO, GC, Co-Founder & Director
  • Former National Leader, Legal Market at Deloitte
  • Former partner at an internationally renowned law firm
  • Advised complex, regulated industries including pharma on litigation, compliance and growth strategy
  • Founding executive, award-winning sports league
JS

Jo-anne Soltesz

Head of Regulatory
  • 30+ years in global pharma regulatory leadership
  • Injectable and generic expertise
  • Experience at Sandoz, Agri Mix and SteriMax
  • Led 50+ Canadian generic drug submissions

Board of directors

Dave Suchon

CEO, Co-Founder & Director

Farris Smith

President, Co-Founder & Director

Chris Burkett

COO, GC, Co-Founder & Director

Riccardo Trecroce

Director
  • Chair of Halton Healthcare
  • Former CEO of Patheon, a multinational pharma manufacturing leader (now part of Thermo Fisher)
  • Senior legal and governance executive

Darryl Firsten

Director
  • Founder of Convocation Flowers, one of North America’s leading graduation retail platforms
  • Chemical engineer with 20+ years building multi-jurisdictional businesses

Zachary Goldenberg

Director
  • Significant Canadian public board experience, including audit committees
  • Corporate and securities lawyer
  • Former Chair of the Audit Committee, Tiidal Gaming Group
  • Former member, TSX Venture Exchange Ontario Advisory Committee